A phase 1/2 study of HKI-272 [neratinib] in combination with trastuzumab (Herceptin) in subjects with advanced breast cancer.
Phase of Trial: Phase I/II
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Neratinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Puma Biotechnology
- 31 Aug 2018 Biomarkers information updated
- 26 Jun 2018 Status changed from active, no longer recruiting to completed.
- 06 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.